⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

February 27, 2026

Operational efficiencies of using one vs multiple bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma in the US.

Tara Graff Savreet Bains Chawla Monika Jun Nicole Heaps Abualbishr Alshreef David J. Tybor Donald C. Moore Nadine Zawadzki Kathryn Spurrier Jason Shafrin

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the operational efficiency of using one versus multiple bispecific antibodies for treating lymphomas.
Comparative analysis of treatment options for diffuse large B-cell lymphoma and follicular lymphoma.
Assessment of time and cost savings associated with single versus multiple bispecific antibodies.
Using a single bispecific antibody is predicted to lead to significant cost savings.
A single bsAb may improve time efficiency in oncology practices.

Implication

Analysis shows single bispecific antibody improves treatment efficiency in lymphoma, suggesting cost benefits for oncology practices.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Graff et al. (2026) studied this question.

synapsesocial.com/papers/69a3d89aec16d51705d2f9e1 https://doi.org/10.1080/14796694.2026.2636559

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Operational efficiencies and cost savings of using one bispecific antibody FDA-approved for both R/R 3L+ DLBCL and FL2025
2Effectiveness and safety of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma (DLBCL): A systematic review and meta-analysis2025
3A Review of Bispecific Antibody Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Implementation in a Community HospitalReview · 2026 · 1 citations
4Bispecific Antibodies—A New Hope for Patients with Diffuse Large B-Cell Lymphoma2025
5Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective2024